NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical ...
Abstract: As industrial systems evolve toward greater automation, adaptability, and intelligence, the demand for real-time processing on heterogeneous multi-dimensional platforms has intensified.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback